CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Nevan Elam

Chief Executive Officer, Rezolute

Search every verified Nevan Elam interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Nevan Elam, CEO of Rezolute Bio, discussed the company's progress in two podcast appearances. In an August 2023 episode, he noted that Rezolute had more than doubled in size to about 55 employees since 2021, citing growth in clinical and clinical operations as the company prepared for late-stage development. He described the company's preparation for a pivotal phase 3 trial of RZ358, a monoclonal antibody for congenital hyperinsulinism, following a $130 million investment. Elam also stated that the company had worked to define clinical success in the pediatric patient population, such as reducing hypoglycemia episodes by at least 25 percent over a 24-hour period, and emphasized the importance of preparing for failure in biotech. In an April 2021 interview, Elam discussed Rezolute's rationale for pursuing therapies for congenital hyperinsulinism and diabetic macular edema using monoclonal antibodies. He described congenital hyperinsulinism as a rare disease affecting about one in 30,000 live births, with multiple genetic mutations, and mentioned FDA incentives like priority review vouchers tied to rare pediatric disease designations. He also addressed challenges in biologic manufacturing, including long lead times and capital investment, and advised maintaining a positive attitude and focus on goals despite obstacles.

Recent appearances

  • Managing Momentum With Rezolute Bio's Nevan Charles Elam, JD

    August 21, 2023 · 📺 Life Science Connect

    ince we last spoke in the Spring of 2021, Nevan Charles Elam, JD has managed to advance both of small-but-mighty Rezolute Bio's candidates onto the next phases of their journey. This year, on the back of a $130 million investment, Rezolute Bio is prepping its RZ358 candidate, a monoclonal antibody for congenital hyperinsulinism, for a pivotal phase 3 trial. On this week's episode of the Business of Biotech, we're settling in for an interrogation of Elam on the management principles of maintaining multi-candidate clinical momentum among highly disparate candidates and raising big dollars as a s…

    Watch on YouTube ↗

  • mAb Manufacturing with Rezolute Bio's Nevan Charles Elam, JD

    April 05, 2021 · 📺 Life Science Connect

    Nevan Charles Elam, JD founded Rezolute Bio ten years ago on the heels of a complex career intersecting law, high tech, and life sciences. On this episode of the Business of Biotech, Elam shares the company's rationale for pursuing congenital hyperinsulinism and diabetic macular edema therapeutics by leveraging monoclonal antibodies and discusses the company's approach to process development and manufacturing. #businessofbiotech #biopharma #biotech #cytiva http://cytiva.com/emergingbiotech Audio version available here: https://www.bioprocessonline.com/doc/... Subscribe to the podcast: App…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →